CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

OTCQB:CYDY - Post by User

CytoDyn Inc

<< Previous

Bullboard Posts

Post by Pandoraon Aug 22, 2024 7:32pm

60 Views

Post# 36192739

Patent Application

I find this very strange for a company that is struggling for positive news. I contacted the company about it and they said "we have it under control" or words to that effect.

What it is is a patent for triple negative breast cancer that was approved for issue after they paid a small fee. They were given a 90 day time frame to pay the fee but it seems they chose to let the time lapse and the patent is now in the "Abandoned" category.

I tried posting this news on the Yahoo board some time ago but I cannot seem to post there. Oh well!

17/148,281 | 230042.431:

METHOD OF TREATING METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) BY ADMINISTERING AN ANTIBODY AGAINST C-C CHEMOKINE RECEPTOR TYPE 5 (CCR5) ANTIBODY

Status

Abandoned -- Failure to Pay Issue Fee 08/21/2024

The fee was about $480 so the amount could not have been a problem.

And they certainly could do with positive news -- but they abandoned it anyway -- I guess they are out of that business. Maybe they can sell the rights to the patent.?